$80.00
Tesamorelin Structure
Sequence (Single Letter): Unk-Tyr-Ala-Asp-Ala-lle-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-lle-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
Molecular Formula: C223H370N72O69S
Molecular Weight: 5195.908 g/mol
PubChem CID: 44147413
CAS Number: 901758-09-6
Tesamorelin, an analogue of growth hormone releasing hormone (GHRH), mirrors the structure of standard GHRH, enhanced by the addition of an extra trans-3-hexanoic acid group. Developed by Theratechnologies in Canada, Tesamorelin earned FDA approval in 2010 as the latest drug for managing HIV-associated lipodystrophy. Beyond its approved use, the peptide has undergone exploration regarding its potential to enhance peripheral nerve regeneration and as a potential intervention for mild cognitive impairment (MCI), which precedes dementia.
If you’ve been waiting to stock up or join the VIP program, now is the time. Once these 100 spots are taken, VIP membership will close again.
